In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer. ★ Support this podcast ★
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Accrual Culture: Top Points for Site Selection - Timelines
Accrual Culture: Top Points for Site Selection - Responsiveness
The GOG Highlight Reel - January 2026
KEYNOTE-B96 FDA APPROVAL REVIEW
Free AI-powered recaps of GOG GYN-LIVE and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.